Summit Therapeutics Inc. vs Abbvie Inc.
SMMT vs ABBV — side-by-side comparison from reported financials. SMMT leads 1, ABBV leads 4 of 5 comparable metrics.
Summit Therapeutics Inc.
SMMT · Healthcare
$17.55+2.21%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | SMMT | ABBV |
|---|---|---|
| Price | $17.55 | $276.43 |
| Market cap | $14.0B | $488B |
| Revenue (TTM) | — | $64.4B |
| Revenue growth | — | +1.8% |
| Net margin | — | 9.8% |
| Free cash flow | -$932M | $18.2B |
| Net cash (debt) | $670M | ($56.2B) |
| 1-year price return | -22.5% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | — | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -169% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 3 of 8 | 9 of 8 |
| Employees | 265 | 57,000 |
Full résumé-style profiles: SMMT CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.